Molecular modeling of a potential new and selective PET radiotracers for the serotonin transporter

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 5, Issue 3, 2002, Pages 245-257

  Wellsow, Julia ^a   Kovar, Karl Artur ^a   Machulla, Hans Jürgen ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,5,6,10B HEXAHYDRO 6 (4 METHYLTHIOPHENYL)PYRROLO[2,1 A]ISOQUINOLINE; 3 AMINO 4 (2 DIMETHYLAMINOMETHYL)PHENYLSULFANYL)BENZONITRILE; 5 IODO 2 [2 (DIMETHYLAMINOMETHYL)PHENYLSULFANYL]BENZYLALCOHOL; ALDEHYDE DERIVATIVE; BIPHENYL DERIVATIVE; CARBON 11; CARBONYL DERIVATIVE; CITALOPRAM; CYANAMIDE; ESTER DERIVATIVE; FLUORINE 18; FLUORINE DERIVATIVE; FLUOXETINE; IMINE; KETONE DERIVATIVE; MOXIFETIN; N,N DIMEHTYL 2 (2 AMINO 4 IODOPHENYLSULFANYL)BENZYLAMINE; N,N DIMETHYL 2 (2 AMINO 4 METHOXYPHENYLSULFANYL)BENZYLAMINE; N,N DIMETHYL 2 (2 AMINO 4 METHYLPHENYLSULFANYL)BENZYLAMINE; NORADRENALIN TRANSPORTER; OXIME; PAROXETINE; RADIOLIGAND; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SULFIDE; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; CARRIER PROTEIN; COTRANSPORTER; LIGAND; MEMBRANE PROTEIN; NERVE PROTEIN; PHENYL SULFIDE; RADIOISOTOPE;

ANALYTIC METHOD; ARTICLE; BINDING AFFINITY; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; MOLECULAR MODEL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; BIOLOGY; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; PROTEIN BINDING; STRUCTURE ACTIVITY RELATION;

CARRIER PROTEINS; COMPUTATIONAL BIOLOGY; DRUG DESIGN; LIGANDS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MODELS, MOLECULAR; NERVE TISSUE PROTEINS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PROTEIN BINDING; RADIOISOTOPES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFIDES; SYMPORTERS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036769075     PISSN: 14821826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Halldin, C., Gulyas, B., Langer, O. and Farde, L., Brain radioligands - state of the art and new trends. Q J Nucl Med, 45 (2):139-152, 2001.
2. Scheffel, U., Dannals, R.F., Suehiro, M., Ricaurte, G.A., Carroll, F.I., Kuhar, M.J. and Wagner, H.N., Jr., Development of PET/SPECT ligands for the serotonin transporter. NIDA Res Monogr, 138:111-130, 1994.
3. Oh, S.J., Ha, H.-J., Chi, D.Y. and Lee, H.K., Serotonin receptor and transporter ligands - current status. Curr Med Chem, 8:999-1034, 2001.
4. Laakso, A. and Hietala, J., PET studies of brain monoamine transporters. Curr Pharm Design, 6:1611-1623, 2000.
5. 11C]citalopram as a radioligand for in vivo labeling of 5-hydroxytryptamine uptake sites. Nucl Med Biol, 19:851-855, 1992.
6. 11C]-sertraline. Appl Radiat Isot, 40:147-151, 1989.
7. 11C]fluoxetine in a monkey brain. Nucl Med Biol, 22:613-616, 1995.
8. Smith, D.F., Jensen, P.N., Gee, A.D., Hansen, S.B., Danielsen, E., Andersen, F., Saiz, P.A. and Gjedde, A., PET neuroimaging with [11C]venlafaxine: serotonin uptake inhibition, biodistribution and binding in living pig brain. Eur Neuropsychopharmacol, 7:195-200, 1997.
9. 11C]-beta-CIT binding to monoamine transporters in the monkey and human brain. Synapse, 16:93-103, 1994.
10. Bergstrom, K.A., Halldin, C., Hall, H., Lundkvist, C., Ginovart, N., Swahn, C.G. and Farde, L., In vitro and in vivo characterisation of nor-beta-CIT: A potential radioligand for visualisation of the serotonin transporter in the brain. Eur J Nucl Med, 24 (6):596-601, 1997.
11. 123I]ZIENT: A new high affinity and selective SERT imaging agent. J Nucl Med, 41 (5 Suppl):39, 2000.
12. Goodman, M.M., Chen, P., Kilts, C., Ely, T., Hoffman, J.M., Votaw, J. and Camp, V., Radiolabeled 2-β-carbomethoxy-3-β-(4-(2-fluoroethyl)-3-iodophenyl -nortropane (FEINT): Synthesis, characterization and in vitro audiography of a potential radioligand for mapping serotonin transporter sites by both PET and SPECT. J Nucl Med, 40 (5 Suppl):306, 1999.
13. 11C](+)McN5652. Synapse, 20:37-43, 1995.
14. 11C]McN5652. J Cereb Blood Flow Metab, 15:798-805, 1995.
15. McCann, U.D., Eligulashvili, V. and Ricaurte, G.A., (+/-)-3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: Clinical studies. Neuropsychobiology, 42:11-16, 2000.
16. McCann, U.D., Szabo, Z., Scheffel, U., Dannals, R. and Ricaurte, G.A., Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. The Lancet, 352:1433-1437, 1999.
17. 123I]IDAM, 5-Iodo-2-((2-((dimethylamino)-methyl)-phenyl)-thio)-benzyl Alcohol. J Med Chem, 42:333-335, 1999.
18. Oya, S., Choi, S.R., Hou, C., Mu, M., Kung, M.P., Acton, P.D., Siciliano, M. and Kung, H.F., 2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): an improved serotonin transporter ligand. Nucl Med and Biol, 27:249-254, 2000.
19. Tarkiainen, J., Vercouillie, J., Guilloteau, D., Gulyas, B., Sovago, J., Cselenyi, Z., Emond, P., Chalon, S., Sandell, J., Hiltunen, J., Farde, L. and Halldin, C., Carbon-11 Labelling of MADAM in Two Different Positions: A Highly Selective PET Radioligand for the Serotonin Transporter. J Labelled Cpd Radiopharm, 44 (1 Suppl):S193-S195, 2001.
20. 11C and evaluation in vivo. J Nucl Med, 41 (5 Suppl):38-39, 2000.
21. 11C]-labeled 2-(phenylthio)araalkylamines. J Med Chem, 43:3103-3110, 2000.
22. Sindelar, K., Pomykacek, J., Valchar, M., Dobrovsky, K., Metysova, J. and Polivka, Z., Potential antidepressants and inhibitors of 5-hydroxytryptamine and noradrenaline re-uptake in the brain: N,N-dimethyl(arylthio)thenylamines and N,N-dimethyl-2-(thienylthio)benzylamines. Collect Czech Chem Commun, 56:449-458, 1991.
23. Ferris, R.M., Brieaddy, L., Mehta, N., Hollingsworth, E., Rigdon, G., Wang, C., Soroko, F., Wastila, W. and Cooper, B., Pharmacological properties of 403U76, a new chemical class of 5-hydroxytryptamine- and noradrenaline-reuptake inhibitor. J Pharm Pharmacol, 47:775-781, 1995.
24. 11C]DASB. Eur J Nucl Med, 27:1719-1722, 2000.
25. Emond, P., Vercouillie, J., Innis, R., Chalon, S., Mavel, S., Frangin, Y., Halldin, C., Besnard, J.-C. and Guilloteau, D., Substituted Diphenyl Sulfides as Selective Serotonin Transporter Ligands: Synthesis and In Vitro Evaluation. J Med Chem, 45:1253-1258, 2002.
26. Huang, Y., Bae, S.A., Zhu, Z., Guo, N., Hwang, D.R. and Laruelle, M., Fluorinated Analogues of ADAM as New PET Radioligands for the Serotonin Transporter: Synthesis and Pharmacological Evaluation. J Labelled Cpd Radiopharm, 44 (1 Suppl):18, 2001.
27. Wellsow, J., Machulla, H.-J. and Kovar, K.-A., 3D QSAR of Serotonin Transporter Ligands: CoMFA and CoMSIA studies. Quant Struct-Act Relat, In print, 2002.
28. SYBYL molecular modeling software, Version 6.6. Tripos Inc.,1699 South Hanley Rd, Suite 303, St. Louis, MO 63144.
29. Jarkas, N., McConathy, J., Ely, T., Kilts, C.D., Votaw, J. and Goodman, M.M., Synthesis and Radiolabling of New Derivatives of ADAM, Potential Candidates as SERT Imaging Agents for PET. J Labelled Cpd Radiopharm, 44 (1 Suppl):S204-S206, 2001.
30. Clark, M., Cramer, R.D., III and Van Opdenbosch, N., Validation of the general purpose Tripos 5.2 force field. J Comput Chem, 10:982-1012, 1989.
31. Jones, G., Willett, P. and Glen, R.C., A genetic algorithm for flexible molecular overlay and pharmacophore elucidation. J Comput-Aided Mol Des, 9:532-549, 1995.
32. Geladi, P. and Kowalski, B.R., Partial least-squares regression: A tutorial. Anal Chim Acta, 185:1-17, 1986.
33. Wold, S., Johansson, E. and Cocchi, M., PSL - Partial Least-Squares Projections to Latent Structures, in: Kubinyi, H (eds), 3D QSAR in Drug Design, Theory, Methods and Applications. Vol. Volume 1, ESCOM, Leiden, pp 523-550, 1993.
34. Cramer, R.D., Patterson, D.E. and Bunce, J.D., Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc, 110:5959-5967, 1988.
35. Klebe, G., Comparative molecular similarity indices analysis: CoMSIA, in: Kubinyi, H, Folkers, G and Martin, YC (eds), 3D QSAR in Drug Design: Recent Advances. Vol. 3, KLUWER / ESCOM, Dordrecht / Boston / London, pp 87-104, 1998.
36. Klebe, G., Abraham, U. and Mietzner, T., Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem, 37:4130-4146, 1994.
37. Owens, M.J., Morgan, W.N., Plott, S.J. and Nemeroff, C.B., Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther, 283:1305-1322, 1997.
38. SYBYL molecular modeling software, Version 6.6, Theory Manual. Tripos Inc.,1699 South Hanley Rd, Suite 303, St. Louis, MO 63144.
39. Sindelar, K., Pomykacek, J., Holubek, J., Svatek, E., Valchar, M., Dobrovsky, K., Metysova, J. and Polivka, Z., Potential antidepressants and selective inhibitors of 5-hydroxytryptamine re-uptake in the brain: synthesis of several potential metabolites of moxifetin and of two A-ring fluorinated analogs. Collect Czech Chem Commun, 56:459-477, 1991.
40. Jilek, J., Sindelar, K., Pomykacek, J., Kmonicek, V., Sedivy, Z., Hrubantova, M., Holubek, J., Svatek, E., Ryska, M. and et al., Potential antidepressants: 2-(methoxy-and hydroxyphenylthio)benzylamines as selective inhibitors of 5-hydroxytryptamine re-uptake in the brain. Collect Czech Chem Commun, 54:3294-3338, 1989.
41. Jilek, J., Urban, J., Taufmann, P., Holubek, J., Dlabac, A., Valchar, M. and Protiva, M., Potential antidepressants. 2-(Phenylthio)aralkylamines. Collect Czech Chem Commun, 54:1995-2008, 1989.
42. 18F-IDAM as a PET Imaging Agent for Serotonin Transporters. J Labelled Cpd Radiopharm, 44 (1 Suppl):S15-S17, 2001.
43. Choi, S.-R., Oya, S., Hou, C. and Kung, H.F., Structure-Activity Relationships of analogs of ADAM as Ligands for Serotonin Transporters. J Labelled Cpd Radiopharm, 44 (1 Suppl):S190-S192, 2001.
44. 123I]ODAM as a Serotonin Transporter Imaging Agent. J Labelled Cpd Radiopharm, 42 (1 Suppl):S357-S359, 1999.
45. 123I]ODAM. Eur J Nucl Med, 26:1359-1362, 1999.
46. 18F]AFM, a selective PET tracer for the serotonin transporter. J Nucl Med, 43 (5 Suppl):358P, 2002.
47. Oya, S., Kung, M.-P., Hou, C., Acton, P.D., Mu, M. and Kung, H.F., Structure-Activity Relationships of IDAM and its Derivatives as Serotonin Transporter Imaging Agents. J Labelled Cpd Radiopharm, 42 (1 Suppl):S57-S59, 1999.
48. Langmuir, I., Isomorphism, isosterism and covalence. J Am Chem Soc, 41:1543-1559, 1919.
49. Grimm, H.G., Structure and size of the non-metallic hydrides. Z Elektrochem, 31:474-480, 1925.
50. Friedman, H.L., Influence of Isosteric Replacement upon Biological Activity, National Academy of Sciences - National Research Council Publication No 206. Vol., Washington D.C., pp 295, 1951.
51. (Burger, A., A reappraisal of bioisosterism. Pharm Acta Helv, 38:705-709, 1963.
52. Burger, A., Isosterism and bioisosterism in drug design. Prog Drug Res, 37:287-371, 1991.
53. Hansch, C., Bioisosterism. Intra-Science Chem Rept, 8 (4):17-25, 1974.
54. Lipinski, C.A., Bioisosterism in drug design. Annu Rep Med Chem, 21:283-291, 1986.
55. Thornber, C.W., Isosterism and molecular modification in drug design. Chem Soc Rev, 8:563-580, 1979.
56. Lassen, N.A., Neuroreceptor quantitation in vivo by the steady-state principle using constant infusion or bolus injection of radioactive tracers. J Cereb Blood Flow Metab, 12 (5):709-716, 1992.
57. 11C-MADAM labeled in two different positions - selective for the serotonin transporter. J Nucl Med, 43 (5 Suppl):164P, 2002.
58. Chiu, W.-H., Klein, T.H. and Wolff, M.E., Apparent bioisosteric replacement of -S- by NCN: synthesis of N-cyano-2-aza-A-nor-5.alpha.-androstan-17.beta.-ol acetate, an azasteroid androgen. J Med Chem, 22:119-120, 1979.
59. 13C]cyanogen bromide, useful electrophilic labeling precursors. Acta Chem Scand, 47:974-978, 1993.